Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine


VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.

"The THEVAX HBV vaccine has been developed employing our company patented technology platform, which has enabled us to proceed from process development into cGMP production in a much shorter period of time. We are pleased to partner with Biotechpharma as our CDMO for cGMP manufacturing of our molecule entering clinical trials. Biotechpharma' s excellent track record, expertise and capabilities to timely deliver a high quality product will play a significant role in the success of this program," says KinKai (Ben) Hwang, CSO of TheVax Genetics Vaccine CO., Ltd.

"We are delighted to be working with TheVax Genetics Vaccine CO on this exciting project and with great enthusiasm look forward to seeing it enter clinical trials," comments Vladas Bumelis, CEO of Biotechpharma. "Biotechpharma is well positioned to facilitate successful process transfer and manufacture of HBV vaccine in rapid time-frames, with focus on high quality and excellence in service."

About TheVax Genetics Vaccine CO., Ltd

TheVax Genetics Vaccine CO. Ltd is a publicly traded Taiwan-based company engaged in development of human vaccines. The Company's main products include therapeutic monovalent vaccines TVGV-1 and multivalent vaccines TVGV-2 for treatment of cervical cancer and precancerous lesions, and therapeutic vaccines TVGV-HBV for treatment of Hepatitis B.

www.vaxgenetics.com.tw

About Biotechpharma UAB 

Biotechpharma UAB is a leading biopharmaceutical CDMO providing fully integrated process development and GMP manufacturing services globally.  Biotechpharma has extensive experience in the production of new biological entities, having 150 employees at its state-of-the-art facility in Vilnius, Lithuania.

www.biotechpharma.lt

 

SOURCE Biotechpharma UAB


These press releases may also interest you

at 01:54
Continuous efforts to improve profits, competitiveness, and cash flowQ1/2024 (year-on-year) Sales decreased by 20% to EUR 2,164 (2,721) million.Adjusted EBIT decreased to EUR 156 (234) million.Adjusted EBIT margin was 7.2% (8.6%).Operating result...

at 01:38
The Barcelona R&D Center ("the Center") of Wanhua Chemical (SHA:600309; "the Company"), located at Cornella de Llobregat, has officially opened its doors as a pivotal move by the company to advance its footprint in Europe and beyond with a quicker...

at 01:35
Regulatory News: Pernod Ricard (Paris:RI): Press Release ? Paris, 25 April 2024 This robust performance illustrates the strength of our diversified portfolio of premium international spirits and our broad-based geographic footprint covering...

at 01:30
Happiest Minds Technologies Limited (NSE: HAPPSTMNDS), a 'Born Digital. Born Agile', Mindful IT Company, today announced it signed definitive agreements to acquire 100% of the equity share capital of PureSoftware Technologies Private Limited...

at 01:21
Aker Solutions has delivered strong revenue growth and improved profitability in the first quarter of 2024 compared to the same period last year. With a solid backlog and high tendering activity, the company is well positioned for future profitable...

at 01:18
First Quarter Highlights            HMH delivered an EBITDA (adj.) of USD 33 million in quarter, about 75% increase year-over-year driven by higher aftermarket activityNES Fircroft delivered 17% increase in EBITDA and 12% revenue growth...



News published on and distributed by: